Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer.

Joline S J LimAndrea L A WongSamuel Guan Wei Ow Natalie Yan Li NgoiGloria H J ChanYvonne L E AngWan Qin ChongSiew Eng LimYi Wan LimMatilda X LeeJoan R E ChooHon Lyn Tan Wei Peng Yong Ross Andrew Soo David Shao Peng Tan Cheng Ean Chee Raghav Sundar Kritika Yadav Supriya Jain Ling-Zhi WangBee Choo TaiBoon Cher GohSoo-Chin Lee

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Lenvatinib plus letrozole had manageable toxicity, with target engagement and preliminary antitumor activity observed, supporting further assessment in randomized studies.

Keyphrases

positive breast cancer
polycystic ovary syndrome
open label
double blind
early breast cancer
oxidative stress
social media
bone mineral density
clinical trial
randomized controlled trial
phase iii
placebo controlled
type diabetes
phase ii
oxide nanoparticles
breast cancer risk